Opportunity Information: Apply for RFA HL 09 003
Apply for RFA HL 09 003
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "NHLBI Pediatric Cardiac Genomics Consortium (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.837 Cardiovascular Diseases Research.
- This funding opportunity was created on Dec 4, 2008 and posted on Dec 4, 2008.
- Applicants must submit their applications by Feb 6, 2009. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Private institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Non domestic (non U.S.) Entities (Foreign Organizations) Tribally Controlled Colleges and Universities (TCCUs) .
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NHLBI Pediatric Cardiac Genomics Consortium (U01) funding opportunity (RFA HL 09 003) was a National Institutes of Health initiative, jointly promoted with the Canadian Institutes of Health Research (CIHR), to build a coordinated research network focused on the genetic and genomic foundations of congenital heart disease (CHD). The central aim was to move beyond isolated, single-site studies by creating a cooperative consortium that could assemble sufficiently large and well-characterized patient and family cohorts, apply modern genetic and genomic approaches, and generate results that improve understanding of both why congenital heart malformations occur and why outcomes vary so widely among individuals who share the same diagnosis. In practical terms, the program emphasized clinical and translational research, meaning it was designed to connect genetic discovery work to real-world patient phenotypes, clinical trajectories, and longer-term outcomes.
Structurally, the initiative planned a consortium made up of up to six Research Centers, along with shared Cores and a Steering Committee to guide scientific direction, coordination, and common operating practices. Applicant Research Centers were expected to propose rigorous, detailed studies targeting the genetics and genomics of one or more specific human cardiac malformations. The intent was twofold: identify causative genes and variants contributing to the development of congenital heart defects, and identify genetic factors that influence outcomes in people living with CHD (for example, differences in postoperative course, complications, functional status, or other clinically meaningful endpoints). A defining feature of the consortium model was shared recruitment and collaboration: individual centers would not operate as independent silos, but would work together to recruit individuals with congenital heart disease and their families in a way that supported all consortium projects and enabled cross-center analyses.
This program was positioned as part of a broader NHLBI translational effort in pediatric cardiovascular disease. It was explicitly linked to a companion NHLBI Cardiac Development Consortium and to a separate Administrative Coordinating Center that would support operations across both consortia. The broader ecosystem also included interaction with the NHLBI Pediatric Heart Network, with the stated purpose of accelerating translation in both directions: moving basic science discoveries toward clinical research and, just as importantly, allowing clinical priorities and unmet needs to inform what basic and genomic research questions should be pursued next. In other words, the opportunity was designed to create a pipeline from gene discovery to clinically relevant knowledge, supported by coordinated infrastructure and active collaboration.
The mechanism of support was a Research Project Cooperative Agreement (U01). This matters because a U01 is not a standard investigator-initiated grant with minimal federal involvement; it is a cooperative agreement that typically includes substantial programmatic participation from the funding institute. In a consortium context, that generally aligns with expectations for shared governance, common protocols, coordinated data approaches, and active steering committee engagement to keep multi-site work aligned and productive.
On funding, NHLBI indicated an intention to commit about $1.44 million in total costs in fiscal year 2009, and projected a maximum total of $25.44 million in total costs across the full six-year project period for the consortium as a whole. The announcement anticipated making up to six Research Center awards. No cost sharing or matching requirement was listed.
Eligibility was broad and included a wide range of organizational types: state governments; public and private institutions of higher education; nonprofits (including 501(c)(3) and non-501(c)(3) entities); for-profit organizations other than small businesses as well as small businesses; and additional categories such as Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), eligible federal agencies, and non-U.S. entities (foreign organizations). The opportunity fell under the Health funding activity category and was associated with CFDA 93.837 (Cardiovascular Diseases Research).
Administratively, the opportunity was posted on December 4, 2008, with an original and current closing date of February 6, 2009, and it was later archived on March 9, 2009. The sponsoring agency was the National Institutes of Health (with NHLBI leading), and the full announcement was hosted on the NIH grants site under the RFA HL 09 003 listing.
Frequently Asked Questions (FAQs)
What is the NHLBI Pediatric Cardiac Genomics Consortium (U01) funding opportunity?
It was a National Institutes of Health (NIH) initiative led by the National Heart, Lung, and Blood Institute (NHLBI), jointly promoted with the Canadian Institutes of Health Research (CIHR), to create a coordinated research network focused on the genetic and genomic foundations of congenital heart disease (CHD). The opportunity is identified as RFA HL 09 003.
What was the main goal of this consortium initiative?
The central goal was to move beyond isolated, single-site studies by building a cooperative consortium that could assemble large, well-characterized patient and family cohorts, apply modern genetic and genomic approaches, and produce findings that improve understanding of why congenital heart malformations occur and why outcomes can vary widely among individuals with the same diagnosis.
What kinds of research did the program emphasize?
The program emphasized clinical and translational research, meaning genetic and genomic discovery efforts were expected to be connected to real-world patient phenotypes, clinical trajectories, and longer-term outcomes.
How was the consortium expected to be structured?
The planned structure included up to six Research Centers, shared Cores, and a Steering Committee to guide scientific direction, coordination, and common operating practices.
How many awards were anticipated under this opportunity?
The announcement anticipated making up to six Research Center awards.
What were Research Centers expected to propose?
Applicant Research Centers were expected to propose rigorous, detailed studies targeting the genetics and genomics of one or more specific human cardiac malformations.
What were the two primary scientific aims for the proposed studies?
The intent was (1) to identify causative genes and variants contributing to the development of congenital heart defects, and (2) to identify genetic factors that influence outcomes in people living with CHD, such as differences in postoperative course, complications, functional status, or other clinically meaningful endpoints.
Was collaboration between centers required, or could sites operate independently?
Collaboration was a defining feature. Centers were not expected to operate as independent silos; they were expected to work together to recruit individuals with CHD and their families in a way that supported all consortium projects and enabled cross-center analyses.
What is the funding mechanism for this opportunity?
The mechanism of support was a Research Project Cooperative Agreement (U01).
Why does the U01 cooperative agreement mechanism matter?
A U01 is not a standard investigator-initiated grant with minimal federal involvement. It is a cooperative agreement that typically includes substantial programmatic participation from the funding institute. In a consortium setting, that generally aligns with expectations for shared governance, common protocols, coordinated data approaches, and active Steering Committee engagement to keep multi-site work aligned.
How did this opportunity fit into broader NHLBI efforts?
It was positioned as part of a broader NHLBI translational effort in pediatric cardiovascular disease. It was explicitly linked to a companion NHLBI Cardiac Development Consortium and to a separate Administrative Coordinating Center intended to support operations across both consortia.
Was there an expectation to interact with other NHLBI programs?
Yes. The ecosystem described included interaction with the NHLBI Pediatric Heart Network, with the stated purpose of accelerating translation in both directions: moving basic science discoveries toward clinical research and enabling clinical priorities and unmet needs to inform future basic and genomic research questions.
What was the planned funding level for the consortium?
NHLBI indicated an intention to commit about $1.44 million in total costs in fiscal year 2009 and projected a maximum total of $25.44 million in total costs across the full six-year project period for the consortium as a whole.
Was cost sharing or matching required?
No cost sharing or matching requirement was listed in the provided information.
Who was eligible to apply?
Eligibility was broad and included state governments; public and private institutions of higher education; nonprofits (including 501(c)(3) and non-501(c)(3) entities); for-profit organizations (including small businesses and other than small businesses); eligible federal agencies; and non-U.S. entities (foreign organizations). Additional eligible categories included Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs).
Were foreign (non-U.S.) organizations eligible?
Yes. The eligibility list included non-U.S. entities (foreign organizations).
What was the funding activity/category associated with this opportunity?
The opportunity fell under the Health funding activity category.
What CFDA number was associated with this program?
It was associated with CFDA 93.837 (Cardiovascular Diseases Research).
Which agency sponsored the opportunity?
The sponsoring agency was the National Institutes of Health (NIH), with NHLBI leading.
When was the opportunity posted and when did it close?
It was posted on December 4, 2008. The original and current closing date was February 6, 2009.
Was this opportunity later archived?
Yes. It was later archived on March 9, 2009.
Where was the full announcement hosted?
The full announcement was hosted on the NIH grants site under the RFA HL 09 003 listing.
What disease area and patient population did the program focus on?
The focus was on congenital heart disease (CHD) in pediatric cardiovascular disease, with an emphasis on understanding genetic and genomic contributors to congenital heart malformations and outcome variability.
What was the practical reason for building large patient and family cohorts?
The consortium model aimed to assemble sufficiently large and well-characterized cohorts to support modern genetic and genomic analyses and to enable cross-center analyses that are often not feasible in single-site studies.
What kinds of outcomes did the program description highlight as relevant?
Examples mentioned included postoperative course, complications, functional status, and other clinically meaningful endpoints among individuals living with CHD.
Browse more opportunities from the same category: Health
Next opportunity: NHLBI Pediatric Translational Consortium Administrative Coordinating Center (U01)
Previous opportunity: 1000 Genomes Project Dataset Analysis (U01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 09 003
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 09 003) also looked into and applied for these:
| Funding Opportunity |
|---|
| NHLBI Pediatric Translational Consortium Administrative Coordinating Center (U01) Apply for RFA HL 09 011 Funding Number: RFA HL 09 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Cardiac Translational Research Implementation Program (C TRIP) (P20) Apply for RFA HL 10 001 Funding Number: RFA HL 10 001 Agency: National Institutes of Health Category: Health Funding Amount: $499,999 |
| Patient Reported Outcomes Measurement Information System (PROMIS) Network Center (U54) Apply for RFA RM 08 022 Funding Number: RFA RM 08 022 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Patient Reported Outcomes Measurement Information System (PROMIS) Research Sites (U01) Apply for RFA RM 08 023 Funding Number: RFA RM 08 023 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Patient Reported Outcomes Measurement Information System (PROMIS) Technology Center (U54) Apply for RFA RM 08 024 Funding Number: RFA RM 08 024 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Patient Reported Outcomes Measurement Information System (PROMIS) Statistical Center (U54) Apply for RFA RM 08 025 Funding Number: RFA RM 08 025 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAMS Small Grant Program For New Investigators (R03) Apply for PAR 09 031 Funding Number: PAR 09 031 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Malaria Communities Program FY09 RFA Apply for M OAA GH 09 252 Funding Number: M OAA GH 09 252 Agency: Agency for International Development Category: Health Funding Amount: $1,500,000 |
| Influenza and Other Emerging Infectious Diseases in Vietnam (U01) Apply for RFA IP 09 002 Funding Number: RFA IP 09 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Research and Public Health Practice on Influenza and other respiratory infectious diseases in the Middle East, Southeast Asia, and South American regions Apply for RFA IP 09 004 Funding Number: RFA IP 09 004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $3,000,000 |
| Academic Research Enhancement Award (R15) Apply for PA 06 042 Funding Number: PA 06 042 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCD Patient Oriented Research Grant (R21) Apply for PA 06 086 Funding Number: PA 06 086 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| NIDCR Small Research Grants for Data Analysis and Statistical Methodology (R03) Apply for PAR 06 211 Funding Number: PAR 06 211 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Retirement Economics (R03) Apply for PA 06 235 Funding Number: PA 06 235 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Retirement Economics (R21) Apply for PA 06 236 Funding Number: PA 06 236 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Ancillary Studies to the AD Neuroimaging Initiative (R03) Apply for PA 06 240 Funding Number: PA 06 240 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Ancillary Studies to the Ad Neuroimaging Initiative (R21) Apply for PA 06 241 Funding Number: PA 06 241 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Aging Musculoskeletal and Skin Extracellular Matrix (R21) Apply for PA 06 242 Funding Number: PA 06 242 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| From Intervention Development to Services Exploratory Research Grants (R34) Apply for PAR 06 248 Funding Number: PAR 06 248 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| Rapid Assessment Post Impact of Disaster (R03) Apply for PAR 06 252 Funding Number: PAR 06 252 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 09 003", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.